LabCorp’s CRO unit Covance has updated its Xcellerate platform to seek out as well as help restore and continue ongoing trials hit by the pandemic.
The so-called Xcellerate COVID-19 solution is a “comprehensive approach to reinitiate ongoing research and start up new studies, with a focus on patient safety and study delivery,” Covance said in a statement.
Designed in conjunction with Covance’s COVID-19 Operational Recovery Team, the Xcellerate COVID-19 solution offers integrated data collection, actionable views of critical study data, COVID-19 targeted risk management and recovery assessment.
In essence, it allows Covance’s teams to oversee trials using near real-time data and analytics and to try to keep things on track if and when studies are hit by pandemic fallout, for example if a highnumber of patients drop out. It is essentially trying to put out fires before they begin by using tweaked new tools to help find a way through the unique problems posed by the pandemic.
“In the same way the global scientific and research community has mobilized to battle the COVID-19 pandemic, we must apply the same innovation and rigor to resuming ongoing research,” said Jonathan Shough, chief information officer of LabCorp’s drug development business.
“The Xcellerate COVID-19 solution enables study teams and sponsors to respond to changing facts on the ground with near-real-time, data-driven analytics and consumer-grade visualizations. Our data-driven, real-world approach provides a platform for the safe and rapid restoration of essential research. Patients deserve nothing less.”